ERSP trims MytoSlim fat burn claims
This article was originally published in The Tan Sheet
Executive Summary
Weight Management Institute discontinues marketing claims that its weight-loss supplement can "increase fat burning enzyme activity up to 10 times normal levels" and help users "lose up to 3 times more body fat" amid an Electronic Retailing Self-Regulation Program inquiry. Brea, Calif.-based WMI substantiated the claim that MytoSlim enables "200% more weight loss than diet and exercise alone," ERSP said June 24. The Council of Better Business Bureaus program made similar recommendations for nearly identical claims for Zylotrim, which contains 7-Keto DHEA, the same active ingredient as MytoSlim (1"The Tan Sheet" March 30, 2009, In Brief)
You may also be interested in...
Fat-burning claim fails
Claims that Zylotrim weight-loss supplements more than doubles fat-burning enzyme activity are not supported and should be modified or discontinued, the Electronic Retailing Self-Regulation Program says. The Carlsbad, Calif.-based firm by the same name said it will modify that claim, and a second claim that 80 percent of each pound users lose is "pure body fat." In its March 23 decision, ERSP also determined the firm supported its claim that product users lost 200 percent more weight in combination with diet and exercise compared to subjects who dieted and exercised but did not use the product in two controlled clinical studies on the active ingredient, 3-acetyl-7-oxo-dehydroepiandrosterone. Zylotrim also provided a reasonable basis for the claim that the product is "clinically proven to help reduce body fat and weight.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.